Trials / Terminated
TerminatedNCT02625376
Resveratrol for Exudative Age-Related Macular Degeneration
Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.
Detailed description
Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration. Comparison of incidence of choroidal neaovascularization between each study group will be performed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Resvega | Dietary supplementation with Resvega BD |
| DIETARY_SUPPLEMENT | Trans-Resveratrol | Dietary supplementation with resveratrol 250 mg BD |
| DIETARY_SUPPLEMENT | placebo | Dietary supplementation with a placebo BD |
Timeline
- Start date
- 2015-08-06
- Primary completion
- 2016-10-26
- Completion
- 2016-11-09
- First posted
- 2015-12-09
- Last updated
- 2020-06-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02625376. Inclusion in this directory is not an endorsement.